Sergio Roman

Paris, 75005, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 101 publications

Reference-free RNA profiling predicts triple negative breast cancer chemoresistance to neoadjuvant treatment.

Reference-free RNA profiling predicts triple negative breast cancer chemoresistance to neoadjuvant treatment.

Journal: NAR cancer
Published: March 06, 2025

Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients.

Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients.

Journal: Cancers
Published: July 09, 2024

Lineage commitment pathways epigenetically oppose oncogenic Gαq/11-YAP1 signaling in dormant disseminated uveal melanoma.

Lineage commitment pathways epigenetically oppose oncogenic Gαq/11-YAP1 signaling in dormant disseminated uveal melanoma.

Journal: bioRxiv : the preprint server for biology
Published: March 18, 2024

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.

Journal: Nature communications
Published: March 05, 2024

Centrosome amplification primes ovarian cancer cells for apoptosis and potentiates the response to chemotherapy.

Centrosome amplification primes ovarian cancer cells for apoptosis and potentiates the response to chemotherapy.

Journal: PLoS biology
Published: November 23, 2023

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study.

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study.

Journal: Current oncology (Toronto, Ont.)
Published: August 14, 2023

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.

Journal: Cancers
Published: March 03, 2023

Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103].

Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103].

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 03, 2023

Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma.

Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma.

Journal: Annals of surgery
Published: February 27, 2023

Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.

Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.

Journal: British journal of cancer
Published: February 08, 2023

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target.

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target.

Journal: Cell death discovery
Published: November 03, 2022

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts.

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts.

Journal: Frontiers in oncology
Published: June 03, 2022
Showing 1-12 of 101

Last Updated: 09/26/2026